Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer

NCT02726503 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Thyroid Cancer

Interventions

DRUG: Lenvatinib

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan